To read the full story, subscribe or sign in.

Intec and Decoy will merge to advance tumor and viral infections therapies

March 15, 2021

Intec Pharma Ltd. is merging with privately held Decoy Biosystems Inc. and the combined company will continue advancing Decoy’s immunotherapy technology for treating a variety of tumors and chronic viral infections.

BioWorld Deals and M&A Cancer Infection

Today's news in brief

BioWorld

BioWorld briefs for March 10, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

MSD synthesizes α-synuclein PET agents

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...